ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Innovent Biologics, Inc. clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 218 studies whose lead sponsor is Innovent Biologics, Inc. or one of 4 companies grouped under it. 59 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 17, 2026.

Our grouping of 4 registry names, not the registry’s. See them and correct one ↓

Compare Innovent Biologics with Eli Lilly and Regeneron Pharmaceuticals →

Pipeline: 40 programs

Each counted once: 40 with a study Innovent Biologics, Inc. leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)

The 5 of 15 with the most live studies.

Program
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363IBI363Phase 3 · 10 live · Melanoma · primary completion Nov 2026☆ Track
mazdutidePhase 3 · 8 live · Obesity · primary completion Dec 2026☆ Track
sintilimabIBI308Phase 3 · 5 live · Carcinoma, Non-Small-Cell Lung · primary completion Mar 2030☆ Track
arcotatug tavatecanPhase 3 · 5 live · Pancreatic Neoplasms · primary completion Dec 2026☆ Track
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003Phase 3 · 4 live · Multiple Myeloma · primary completion Dec 2026☆ Track

10 more in phase 3 — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Innovent Biologics, Inc.’s own registered studies; Innovent Biologics, Inc.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

Licenses and deals

One of Innovent Biologics’ programs has a dated deal behind it: 1 brought in. Each from the companies’ own releases and filings, linked; the registry does not record them.

Brought in 1

What it is testing

The drugs Innovent Biologics, Inc.’s studies test, most open studies first — 50 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 20 more

The first 30 of 50; every drug is on its own page, and each page lists its sponsors.

Coming up

36 of Innovent Biologics, Inc.’s studies under way reach primary completion within a year, 8 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. 1N’26
  2. 10D
  3. 2J’27
  4. 3F
  5. 1M
  6. 1A
  7. 2M
  8. 8J
  9. 1J
  10. 1A
  11. 2S
  12. 2O
  13. 2N

The 12 nearest

Show 7 more

Add all 36 to your calendar (.ics) → With an account.

All 218 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now5927%Recruiting 46 · Not yet recruiting 13
  • Under way, not recruiting2210%
  • Completed10448%
  • Stopped early2411%Terminated 17 · Suspended 4 · Withdrawn 3
  • Status unknown or other94%

Phase

  • Phase 1125
  • Phase 266
  • Phase 350
  • Early Phase 12
  • Phase 41

Where

  • China199
  • United States14
  • Australia13
  • France2
  • Spain2
  • Japan2

Over the years

  1. 16
  2. 17
  3. 18
  4. 19
  5. 20
  6. 21
  7. 22
  8. 23
  9. 24
  10. 25
  11. 3826

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Innovent Biologics, Inc.

  • Innovent Biologics (Suzhou) Co. Ltd.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    199 studies →
  • Innovent Biologics Technology Limited (Shanghai R&D Center)
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    7 studies →
  • Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    7 studies →
  • Fortvita Biologics (USA)Inc.
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    5 studies →

Focus areas

Conditions Innovent Biologics, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 218. Browse all 218 →